Although ADCs are helping treat solid tumors, particularly HER2+ breast cancer, their unique toxicities require careful monitoring.   To improve efficacy and safety, future research will focus on overcoming resistance, combination therapies, and next-generation treatments. Here, ERBB2 is linked to breast cancer.